KATP channel openers (KCOs) are used clinically for hypertension and angina pectoris.42 These drugs bind at a common site in SUR2, formed of multiple transmembrane helices from TMD1 and TMD2.43,44 All truncations identified here are expected to abolish or disrupt this binding site, with the possible exception of SUR2[Phe1405SerfsTer8], in which the truncation occurs after TMD2. The gene discussed is ABCC9; the disease is hypertensive disorder.